Patent ID: 11944612
Assignee: GLOBAL BLOOD THERAPEUTICS, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 8:
9. The capsule dosage form of claim 8, wherein the capsule contains 300 mg+/−5% of the crystalline ansolvate form compound; wherein the crystalline ansolvate form of compound 1 is substantially free of Form I and/or N; wherein Form I is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 12.820, 15.740, 16.030, 16.630, 17.60°, 25.14°, 25.820 and 26.44020 (each X0.2 020); and wherein Form N is characterized by at least three X-ray powder diffraction peaks (Cu Ka radiation) selected from 11.650, 11.850, 12.080, 16.700, 19.650 and 23.48020 (each ±0.2 020).